On February 9, senxuan Pharmaceutical (830946. BJ), which has attracted much market attention recently due to the concept of “covid-19 specific drug”, announced that Tong Zhenming, the second largest shareholder of the company, plans to reduce its shares by centralized bidding no more than 4.27 million shares in the six months from March 3, 2022 to September 2, 2022, with a reduction ratio of no more than 1%. The reason for the reduction is personal capital demand.
On January 28, senxuan pharmaceutical released the announcement of lifting the restrictions on the sale of shares. The trading date of shares held by major shareholders Jinghua Pharmaceutical Group Co.Ltd(002349) (002349. SZ) and Tong Zhenming is February 9, 2022. Tong Zhenming announced the reduction plan on the day of lifting the ban. According to the public offering prospectus of senxuan medicine, Tong Zhenming worked for senxuan medicine from October 2008 to March 2020, and successively served as executive director and general manager, director and general manager and consultant
Photo source: screenshot of senxuan medical announcement
Due to the market speculation that senxuan medicine may be a supplier of Pfizer specific drugs, the company’s share price continued to rise. Although the company has denied the above rumors, the share price still exceeded 30 yuan / share for a time. Previously, on January 20, the company’s director Cheng Jian, director and deputy general manager Jiang Chunjuan, and Director Secretary and financial director Zhu Shizhang also announced the reduction of holdings, with a total reduction of no more than 75000 shares.
